Tag: mental health

LSD and Magic Mushrooms Dramatically Rewire the Brain, New Study Reveals

From ketamine drips to microdosing on LSD, psychedelics are shaking up the way we approach and treat mental health. A growing body of scientific evidence shows that these long-stigmatized substances could be potential antidepressants, alleviating symptoms by slipping into areas of the brain traditional SSRIs can’t reach, and encouraging new neural connections.

Despite these advances, psychedelics remain fairly mysterious. Researchers haven’t yet pinned down the various mechanisms through which they work inside our bodies. But now, they might be one step closer.

An international team of scientists led by the University of Helsinki in Finland believes they’ve struck biochemical gold. In a study published Monday in the journal Nature Neuroscience, the researchers found that psychedelics psilocin (the primary chemical in magic mushrooms) and LSD exert an antidepressant effect by binding to a protein, receptor tyrosine kinase beta (TrkB), which then activates brain-derived neurotrophic factor (BDNF), a protein that plays a crucial role in the growth, development, and maintenance of neurons; kind of like Miracle-Gro for the brain.

“I think [this study] is very exciting,” Greg Fonzo, co-director of the Center for Psychedelic Research and Therapy at The University of Texas at Austin’s Dell Medical School, who wasn’t involved in the study, tells Inverse. “It establishes a potential common mechanism for psychedelics along with other kinds of antidepressant treatments.” The researchers hope that this new information could potentially lead to creating more effective treatments for mental health disorders.

Keep reading

Science recently uncovered these 5 fascinating facts about psychedelic substances

Scientists are interested in studying psychedelic substances because they have the potential to alter perception, cognition, and mood in ways that may be beneficial for treating a variety of mental health conditions. Some studies suggest that certain psychedelics may have therapeutic effects for conditions such as depression, anxiety, PTSD, addiction, and end-of-life anxiety.

The most commonly studied psychedelic drugs include psilocybin (the active compound found in “magic” mushrooms), lysergic acid diethylamide (LSD, also known simply as “acid”), dimethyltryptamine (or DMT, a naturally occurring psychedelic compound found in many plants and animals), and 3,4-methylenedioxymethamphetamine (known as MDMA or molly, a synthetic drug that produces both psychedelic and stimulant effects).

Below are five recent scientific discoveries related to psychedelic substances and their therapeutic potential.

Keep reading

Arizona funds research into ‘magic mushrooms’ to treat PTSD and depression

Arizona is headed toward funding the first controlled clinical trials for whole mushroom psilocybin, or “magic mushrooms,” to treat an array of health issues, including post-traumatic stress disorder, anxiety and depression. 

The state’s nearly $18 billion 2024 budget contains a provision providing $5 million for whole mushroom psilocybin trials. The money is the culmination of the efforts of Dr. Sue Sisely, an internal medicine physician and principal investigator at Scottsdale Research Institute, which conducts nonprofit drug development research on psychedelics, along with a bipartisan group of state legislators. 

“We’re thrilled that the research on natural mushrooms will finally be able to move forward, so this is a big achievement that finally we’re going to get objective data,” Sisely told the Arizona Mirror. “This will give us reliable insight into how these mushrooms might help or harm people. We need to learn more about how this works.”

Keep reading

Magic mushroom guides in Oregon face uncertain trip ahead

In the last few weeks, dozens of students have graduated from schools in Oregon where they were trained to guide people through magic mushroom trips that can last as long as six hours. At one school, an alpaca farmer, a social worker, an ER nurse and a nutritionist were all in the same class, attempting to learn the tricks of a new trade. 

But it will be a few months until any of them can legally practice what they’ve learned in their state — and once they can, there are open questions about how the psychedelics industry will shape up there.  

“Our big mantra to students is, don’t quit your day job,” said Nathan Howard, the director of one facilitator school called InnerTrek, adding, “Yet.” 

The Oregon state government and 22 training schools are writing the rule book on the best strategy for administering a drug that has shown promise in clinical trials in combatting depression, addiction or dependencies, and anxiety around terminal illnesses.  

 he first licensed magic mushroom guides could be a model for a new sort of health care professional — but are they ready for the realities of the work and how much of a risk are the new guides taking on?  

In November 2020, Oregon voters became the first in the country to approve therapeutic use of psilocybin, which is the key ingredient in magic mushrooms. The drug became legal Jan. 1, 2023, though actual sale of the psychedelic can’t begin until the state gives its stamp of approval to laboratories which will produce the psilocybin products and service centers where they’ll be consumed. Unlike cannabis, magic mushrooms won’t be sold at dispensaries and can only be used under supervision at licensed locations. 

By state law, the supervisors or psilocybin facilitators have to be over 21, have a minimum of a high school education, and they must graduate from a training school before they take a licensing exam. Beyond that, the state entrusts school administrators to vet people through the application process and to iron out the specifics of what a day on the job might entail.  

Keep reading

Helping veterans, battling opioid addiction driving magic mushroom legislation progress

Forty lawmakers, 36 Democrats and 4 Republicans, have co-sponsored a bill aiming to allow for the medical use of psilocybin and a psilocybin therapy grant program, which is currently sitting at the committee level of the Assembly, with its Senate version also in committee. The Assembly bill, A03581, was introduced by Democrat Pat Burke in February. There has been other legislation introduced regarding the hallucinogen as well, with Linda Rosenthal’s version legalizing the adult possession and use of hallucinogens like it.

Research has shown that psilocybin, an organic psychedelic compound, can benefit people with cluster headaches, depression, anxiety, irritable bowel syndrome, ADHD and obsessive compulsive disorder, but it’s getting the most universal traction because of its impact on those suffering from PTSD.

“Psilocybin doesn’t have the huge appeal that marijuana had,” Democrat Assemblyman Phil Steck, who is the Assembly’s Chairman of the Alcoholism and Drug Abuse Committee, says. “But, there are definitely people who make a strong case for the proposition that it helps with PTSD. Certainly we want to do everything that we can to help people that are coming back from war, and if psilocybin has proven to do that, then it should be legal for that purpose.”

Johns Hopkins University has conducted several studies on psilocybin, saying it has substantial antidepressant effects, but needs to be administered under carefully controlled conditions through trained clinicians and therapists.

Keep reading

US could soon approve MDMA therapy — opening an era of psychedelic medicine

For Rick Doblin, 2023 could be a landmark year: the year that the US government decides whether it will allow the use of hallucinogenic drugs to treat mental illness.

Doblin, who is based in Belmont, Massachusetts, is the founder and president of the non-profit organization Multidisciplinary Association for Psychedelic Studies (MAPS). He has spent nearly 40 years researching whether the experience produced by the psychedelic drug MDMA — also called ecstasy or molly — can help people with post-traumatic stress disorder (PTSD). In 2021, MAPS’s phase III clinical trial of 90 people with PTSD found that those who received MDMA coupled with psychotherapy were twice as likely to recover from the condition as were those who received psychotherapy with a placebo1 (see ‘Response to MDMA therapy’).

Keep reading

NEVADA COMMITTEE TO VOTE ON BILL FOR RESEARCH, DECRIMINALIZATION OF PSILOCYBIN

Greg Rea had his first experience with psychedelics when he was 56 years old. Up until then, he’d been a Reno police officer on SWAT for 12 years before retiring from the force to become a pastor and then a real estate investor.

“I retired a couple years ago, but I still was a pretty tightly wound guy,” Rea tells the Weekly in a phone interview. “And I had a seven-days-a-week drinking problem.”

Rea says that despite having a “pretty good life,” like many first responders, alcohol use was adversely affecting him—until about three years ago, when a friend invited him to a group psychedelic experience.

During that experience, which comprised several sessions, a combination of psilocybin [the drug in “magic” mushrooms] and MDMA [aka ecstasy or Molly]took Rea back to two “fairly violent, critical incidents” in which he was involved as a SWAT officer. The intense, emotional trip led to a breakthrough, he says.

“I realized I had some form of PTSD connected to those things,” Rea says. “And I had no idea I’d carried it for almost 20 years.”

After group sessions with other first responders, he began to find a community to talk about mental health—“inner world things” that the wider community might misunderstand. “First responders are exposed to an inordinate amount of human suffering [that] the typical citizen isn’t. So, we said, why don’t we start our own group?”

In the group, firefighters, first responders and current and former military service members are opening up and “finding their healing with psychedelic medicine,” he says. “And I’m free from my seven-days-a-week alcohol habit. My life is just inordinately better. And my relationships are better.”

Rea was one of many who gave public comment during a March 23 hearing for Senate Bill 242 (SB242).

In his testimony, Assemblyman Max Carter said that his therapy with ketamine, the only drug currently legal for psychedelic therapy, has been “transformational” in his mental health and struggle with chronic depression.

“Psilocybin, studies show, is much more powerful. Where I’ve gone through eight or nine ketamine sessions, [it] probably would have been one or two [sessions], if psilocybin was legal,” Carter said, adding that, based on studies, the effects of psilocybin appear to be longer lasting than ketamine.

The bill would establish a framework for research of psilocybin in the state and, if passed as amended, decriminalize possession of the substance, currently listed as a Schedule 1 drug.

Keep reading

In California, Parents May Soon Effectively Lose Custody of Kids 12 and Older 

In California, “stranger danger” may be about to acquire a whole new meaning. 

Forget warning kids. It’s the parents in California who will need to be terrified of strangers if a new bill passes. 

Snuck into AB 665, legislation ostensibly about extending mental health care to lower-income California youths, is a provision that effectively would terminate parents’ rights over their kids as soon as they turn 12. 

The California Family Council warns that this bill “would allow children as young as 12 years old to consent to being placed into state funded group homes without parental permission or knowledge.”  

As long as a mental health professional signs off on it, the kids can go to such a group home—and it doesn’t matter what their parents think. 

“This bill gives a stranger, a school psychologist, power to decide whether a sixth or seventh grader comes home from school that day, and that’s terrifying,” Erin Friday, a California mom of two teens, tells The Daily Signal. 

“This bill is essentially stating that parents are criminals that have to prove their innocence to get their child back,” adds Friday, who is a leader of the parent advocacy group Our Duty. 

Seriously? 

AB 665, which passed out of the Assembly Judiciary Committee last week, builds on a 2010 measure signed into law by then-Gov. Arnold Schwarzenegger, a Republican. That law, the Mental Health Services for At-Risk Youth Act, allowed California children 12 and older to receive mental health care without their parents’ knowledge if a mental health provider determined it was best not to involve the parents.  

That provision was no accident. The Center for American Progress, a liberal think tank, celebrated the California law in a 2010 report as a “useful model for state or federal legislation to address mental illness among LGBT youth.”  

Keep reading

Psychedelics and mental health: Having mystical experiences may yield strongest benefits

It’s a trope seen countless times in books and movies. A character emerges from a drug-induced psychedelic stupor with a fresh outlook and more positive perspective on life. According to new findings from The Ohio State University, however, there may really be some truth to this hallucinogenic notion. Scientists report particularly mystical and insightful psychedelic drug experiences may be associated with an enduring drop in both anxiety and depression symptoms.

Study authors performed a comprehensive machine learning analysis of data pertaining to nearly 1,000 survey respondents who answered questions about their previous non-clinical experiences with psychedelic drugs. Sure enough, those scoring the highest on questionnaires assessing the mystical and insightful nature of their experiences also consistently reported improvements in both depression and anxiety.

Of course, there’s also the risk of encountering a “bad trip.” What happens if a psychedelic experience becomes unpleasant, frightening, or destabilizing? Surprisingly, the study actually found that even challenging psychedelic trips can be beneficial — especially within the context of mystical and insightful experiences. This finding in particular may be especially helpful for practitioners to know as they guide patients through clinical trials focusing on the therapeutic potential of psychedelics.

“Sometimes the challenge arises because it’s an intensely mystical and insightful experience that can, in and of itself, be challenging,” says senior study author Alan Davis, assistant professor and director of the Center for Psychedelic Drug Research and Education in The Ohio State University College of Social Work, in a media release.

Keep reading

Quebec Approves Magic Mushrooms Under Public Health Coverage

Quebec, Canada last week approved the used of psilocybin – the primary psychoactive in “magic mushrooms,” as a valid therapy under the state’s medical system.

Advocates hope the move will set a precedent for other Canadian provinces to take similar action, Forbes reports.

“This decision is a huge step forward for the use of psilocybin-assisted psychotherapy as a legitimate medical treatment,” wrote TheraPsil, a nonprofit group that advocates for the advancement of psilocybin therapies, in a Dec. 15 statement. “It not only provides greater access to this potentially life-changing treatment for patients in Quebec, but it also sets a precedent for other provinces to follow suit.”

Clinical research and other studies into psychedelics such as psilocybin have shown that the drugs have potential therapeutic benefits, particularly for serious mental health conditions such as depression, addiction and anxiety. Research published in the peer-reviewed journal JAMA Psychiatry in 2020 found that psilocybin-assisted psychotherapy was an effective and quick-acting treatment for a group of 24 participants with major depressive disorder. A separate study published in 2016 determined that psilocybin treatment produced substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. -Forbes

As we noted in April, psychedelic mushrooms are becoming increasingly popular in the US as a possible treatment for psychiatric disorders, with their main active ingredient, psilocybin, moving from the fringes of medicine, to become increasingly mainstream. It appears that Canada, however, is actually making moves to bring the benefits to actual patients.

Keep reading